Body Weight Status and Its Association With Patient‐Reported Outcomes in Women With Non‐Metastatic ER ‐Positive Breast Cancer Undergoing Adjuvant Endocrine Therapy
Cancer Medicine · 2026
DOI: 10.1002/cam4.72343 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Danielle Laperche-Santos und 17 weiteren Autor:innen. Beteiligte Einrichtung: CEBROM, Grupo Oncoclinicas, Goiânia, Goiás, Brazil. Hauptthemen laut MEDLINE: Breast Neoplasms, Patient Reported Outcome Measures, Antineoplastic Agents, Hormonal, Body Weight. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To examine associations of body mass index (BMI) with sociodemographic, clinical, treatment‐related, psychosocial, and patient‐reported outcomes among women with non‐metastatic estrogen receptor‐positive (ER+) breast cancer receiving adjuvant endocrine therapy.
Methods
This multicenter cross‐sectional study included 557 women treated at 11 Brazilian public and private institutions from June 2021 to March 2024. Participants were classified as having normal weight, overweight, or obesity. Health‐related quality of life was assessed using the EORTC QLQ‐C30 and QLQ‐BR23. Characteristics were compared across BMI categories using chi‐square or Fisher's exact test and Kruskal–Wallis test. Multinomial logistic regression examined factors associated with BMI category, using normal weight as the reference.
Results
Of 557 participants, 172 had normal weight, 234 were overweight, and 151 had obesity. Education, comorbidities, hospital type, cancer stage, endocrine therapy, axillary dissection, prior chemotherapy, and radiotherapy differed across BMI categories. Participants with obesity had poorer physical functioning and greater pain. In the final model ( n = 554), axillary dissection (OR = 2.51; 95% CI = 1.37–4.59) and continuous medication use (OR = 2.92; 95% CI = 1.78–4.79) were associated with obesity versus normal weight. Tamoxifen was inversely associated with overweight (OR = 0.58; 95% CI = 0.36–0.91), whereas low treatment adherence (OR = 1.54; 95% CI = 1.01–2.35) and continuous medication use (OR = 1.68; 95% CI = 1.10–2.58) were positively associated.
Conclusion
Overweight and obesity were common and associated with sociodemographic, clinical, treatment‐related, and selected quality‐of‐life characteristics. These findings support integrated survivorship care addressing weight‐related health, comorbidities, functional limitations, and symptom burden. Longitudinal studies are needed to clarify temporal relationships.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CEBROM, Grupo Oncoclinicas, Goiânia, Goiás, Brazil.
- Instituto de Ensino e Pesquisa, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
- GBECAM-Grupo Brasileiro de Estudos Em Câncer de Mama, Porto Alegre, RS, Brazil.
- Hospital Sírio-Libanês, Brasília, DF, Brazil.
- Instituto Hospital de Base Do Distrito Federal, Brasília, DF, Brazil.
- Liga Norte Riograndense Contra o Câncer, RN, Brazil.
ORCID-Profile: Danielle Laperche-Santos, Sulene Cunha Sousa Oliveira, Andrea Kazumi Shimada, Renata Arakelian, Yuri Cardoso Rodrigues Beckedorff Bittencourt, Maria Cristina Figueroa Magalhães, Angélica Nogueira-Rodrigues, Daniele Assad-Suzuki
Zitieren
APA
Laperche-Santos, D., Custodio, A. G. C., Moura, F. C., Oliveira, S. C. S., Shimada, A. K., Arakelian, R., Resende, H., Galvão, A. L. Z., Souza, B. S. W., Andrade, M. C. F. M., Bittencourt, Y. C. R. B., Magalhães, M. C. F., Landeiro, L. C. G., Signorini, P. A., Pereira, D. J., Nogueira-Rodrigues, A., Barroso-Sousa, R., & Assad-Suzuki, D. (2026). Body Weight Status and Its Association With Patient‐Reported Outcomes in Women With Non‐Metastatic ER ‐Positive Breast Cancer Undergoing Adjuvant Endocrine Therapy. Cancer Medicine. https://doi.org/10.1002/cam4.72343
Vancouver
Laperche-Santos D, Custodio AGC, Moura FC, Oliveira SCS, Shimada AK, Arakelian R, et al. Body Weight Status and Its Association With Patient‐Reported Outcomes in Women With Non‐Metastatic ER ‐Positive Breast Cancer Undergoing Adjuvant Endocrine Therapy. Cancer Medicine. 2026. doi:10.1002/cam4.72343
BibTeX
@article{LapercheSantos2026,
author = {Laperche-Santos, Danielle and Custodio, Amanda Guimarães Castro and Moura, Fernanda Cesar and Oliveira, Sulene Cunha Sousa and Shimada, Andrea Kazumi and Arakelian, Renata and Resende, Heloisa and Galvão, Anna Luiza Zapalowski and Souza, Bruno Santos Wance de and Andrade, Monalisa Ceciliana Freitas Moreira de and Bittencourt, Yuri Cardoso Rodrigues Beckedorff and Magalhães, Maria Cristina Figueroa and Landeiro, Luciana Castro Garcia and Signorini, Poliana Albuquerque and Pereira, Daniela Jessica and Nogueira-Rodrigues, Angélica and Barroso-Sousa, Romualdo and Assad-Suzuki, Daniele},
title = {Body Weight Status and Its Association With Patient‐Reported Outcomes in Women With Non‐Metastatic ER ‐Positive Breast Cancer Undergoing Adjuvant Endocrine Therapy},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72343}
}
EUVIMED